Proven­tion Bio's J&J-li­censed Crohn's drug stum­bles in mid-stage study

One of the drugs that Old­wick, New Jer­sey-based Proven­tion Bio joined forces with J&J on has failed a mid-stage study.

The com­pa­ny was test­ing the ex­per­i­men­tal ther­a­py, PRV-6527, which was orig­i­nal­ly de­vel­oped by J&J and is de­signed to in­hib­it colony-stim­u­lat­ing fac­tor 1 re­cep­tor (CSF-1R) sig­nal­ing. It was be­ing test­ed in a Phase IIa study, dubbed PRINCE, in 93 mod­er­ate-to-se­vere Crohn’sCrohn’s dis­ease pa­tients who were ei­ther naïve to bi­o­log­ic ther­a­py (~70%) or who had pre­vi­ous­ly failed at least one bi­o­log­ic drug (~30%).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER